The litigation, centered on stock purchases made between July 30, 2025, and February 24, 2026, claims management downplayed an FDA Form 483 inspection as a minor administrative issue. According to the complaint, the document actually identified systemic failures in the company’s quality management and medical device reporting systems. Investors allege these omissions masked the reality of an aggressive dosing algorithm and life-threatening hypoglycemia reports, leading to significant market losses when the truth emerged.

Beta Bionics shares, which reached a peak of $31.99 during the class period, plummeted following the disclosure of an FDA Warning Letter in early 2026. By April 10, 2026, the stock had fallen below $9.00, representing a 72% decline that erased hundreds of millions of dollars in market capitalization. Lead attorney Joseph E. Levi stated that the company failed its obligation to disclose known risks to its public projections. The United States District Court for the Central District of California has set November 3, 2026, as the deadline for shareholders to apply for lead plaintiff status.